Patents Assigned to Arriva Pharmaceuticals, Inc.
  • Patent number: 7914771
    Abstract: The present invention encompasses methods and compositions for the treatment and prevention of chronic obstructive pulmonary disease (COPD) or emphysema, typically smoking-induced emphysema. More specifically, the present invention relates to the treatment and prevention of COPD or emphysema by inhalation of alpha one-antitrypsin (AAT).
    Type: Grant
    Filed: March 9, 2005
    Date of Patent: March 29, 2011
    Assignee: Arriva Pharmaceuticals, Inc.
    Inventors: Philip J. Barr, Philip A. Pemberton, Helen L. Gibson
  • Patent number: 7892825
    Abstract: Vectors, host cells, and methods are provided for the production of proteins in yeast. The vectors generally contain a selection gene, a yeast 2 micron sequence, and a polynucleotide encoding a polypeptide, where the polynucleotide is operably linked to promoter, and where the polynucleotide contains one or more yeast-preferred codons. Host cells are cultured under conditions where, after an initial batch phase, oxygen concentration is kept high and glucose feed is regulated so that the yeast cells stay in respiratory metabolism.
    Type: Grant
    Filed: July 7, 2008
    Date of Patent: February 22, 2011
    Assignee: Arriva Pharmaceuticals, Inc.
    Inventors: Philip J. Barr, Helen L. Gibson
  • Publication number: 20090042278
    Abstract: Vectors, host cells, and methods are provided for the production of proteins in yeast. The vectors generally contain a selection gene, a yeast 2 micron sequence, and a polynucleotide encoding a polypeptide, where the polynucleotide is operably linked to promoter, and where the polynucleotide contains one or more yeast-preferred codons. Host cells are cultured under conditions where, after an initial batch phase, oxygen concentration is kept high and glucose feed is regulated so that the yeast cells stay in respiratory metabolism.
    Type: Application
    Filed: July 7, 2008
    Publication date: February 12, 2009
    Applicant: ARRIVA PHARMACEUTICALS, INC.
    Inventors: Philip J. Barr, Helen L. Gibson
  • Patent number: 7419801
    Abstract: Vectors, host cells, and methods are provided for the production of proteins in yeast. The vectors generally contain a selection gene, a yeast 2 micron sequence, and a polynucleotide encoding a polypeptide, where the polynucleotide is operably linked to promoter, and where the polynucleotide contains one or more yeast-preferred codons. Host cells are cultured under conditions where, after an initial batch phase, oxygen concentration is kept high and glucose feed is regulated so that the yeast cells stay in respiratory metabolism.
    Type: Grant
    Filed: August 9, 2004
    Date of Patent: September 2, 2008
    Assignee: Arriva Pharmaceuticals, Inc.
    Inventors: Philip J. Barr, Helen L. Gibson
  • Patent number: 7247704
    Abstract: Fusion proteins of protease inhibitors are provided, in particular fusion proteins of alpha 1-antitrypsin (AAT) and a second protease inhibitor, such as secretory leukocyte protease inhibitor (SLPI) or tissue inhibitor of metalloproteases (TIMP). Polynucleotides encoding the fusion proteins, vectors comprising such polynucleotides, and host cells containing such vectors are also provided. Methods of making the fusion proteins of the invention are also provide, as well as methods of using the fusion proteins, for example to inhibit protease activity in a biological sample or in the treatment of an individual suffering from, or at risk for, a disease or disorder involving unwanted protease activity.
    Type: Grant
    Filed: December 18, 2001
    Date of Patent: July 24, 2007
    Assignee: Arriva Pharmaceuticals, Inc.
    Inventors: Philip J. Barr, Helen L. Gibson, Philip A. Pemberton